Systasy Named a Top 10 Drug Discovery and Development Solution Provider in Europe

In its annual listing, the magazine names ten companies that are at the forefront of providing drug discovery and development solutions and impacting the industry. The panel chose Systasy, stating that all top 10 companies “demonstrate an ability to develop innovative technologies combined with outstanding customer service.”

Project EXTassay Receives VIP Validation Award

March 26, 2019 – MunichThe German Ministry of Education and Research (BMBF) has assigned the VIP+ validation award 2019 to the EXTassay project. The EXTassay technology allows to directly examine what´s going wrong in neuronal cells of patients suffering from complex brain diseases.

Drug Repurposing Screening Identifies Spironolactone as Potentially Effective Drug to Treat Symptoms of Schizophrenia

Schizophrenia is a complex human disease, caused both by individual genetic variation and lifestyle. Genome-wide association studies have implicated many molecular targets and biological pathways with this disease. One these pathways associated with schizophrenia is the so-called Neuregulin1 (Nrg1)-ERBB4 signaling pathway.

License agreement with Boehringer Ingelheim

Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH(BI) entered a non-exclusive license agreement for cell-based splitSENSOR assays providing BI with the options to screen for selected target activities relevant to schizophrenia.

Patent transfer of Double Switch Technology from Sygnis AG

Systasy Bioscience GmbH and Sygnis AG closed a patent transfer deal today. A patent transfer agreement for Double Switch technology was signed.